Navigation Links
Sequenom Welcomes Myla Lai-Goldman, M.D., To Board Of Directors
Date:9/4/2012

SAN DIEGO, Sept. 4, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the appointment of Myla Lai-Goldman, M.D., to its Board of Directors, effective September 11, 2012. Dr. Lai-Goldman has also been appointed to the Science Committee of the Company's Board of Directors.

Dr. Lai-Goldman is a managing partner at Personalized Science, LLC, and Chief Executive Officer of GeneCentric Diagnostics, Inc. and a Venture Partner with Hatteras Venture Partners. She previously served as Executive Vice President, Chief Medical Officer and Chief Scientific Officer of Laboratory Corporation of America.  She is a recognized author and speaker on clinical diagnostics, including factors that lead to successful adoption of novel technologies.

"We welcome Dr. Lai-Goldman to our board, and look forward to her contributions as a renowned voice in the pathology community to add strategic counsel to our short-term and long-term growth efforts in the diagnostics market," said Harry F. Hixson, Jr., Ph.D., Chairman and CEO, Sequenom, Inc.

Dr. Lai-Goldman received her undergraduate degree in biology from the University of Pennsylvania and her medical degree from Columbia University. She completed a pathology residency and surgical pathology fellowship at UCLA in Los Angeles, and followed with a hematopathology fellowship at the University of North Carolina at Chapel Hill.

"As we continue to advance our role in driving forward the clinical applications of genetic technologies, Dr. Lai-Goldman's extensive experience in clinical laboratory medicine and specifically in molecular diagnostics will be extremely insightful and contribute meaningfully to the Board's Science Committee," said Ronald M. Lindsay, Ph.D., Executive Vice President, Research and Development at Sequenom.

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company's expectations regarding Dr. Lai-Goldman's contributions to the Company,  the Company's short-term and long-term  growth efforts in the diagnostics market, and the Company's intentions and ability to continue to advance its role in driving forward the clinical applications of genetic technologies, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use of the Company's technology and tests such as the MaterniT21 PLUS test, reliance upon the collaborative efforts of other parties, the Company or third parties obtaining or maintaining regulatory approvals that impact the Company's business, government regulation particularly with respect to diagnostic products and laboratory developed tests, publication processes, the performance of designed product enhancements, the Company's ability to develop and commercialize technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's financial position, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others litigation involving the Company, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, including without limitation its Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 and its Annual Report on Form 10-K for the year ended December 31, 2011. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
2. Sequenom Completes International Distribution Agreements To Expand Access To MaterniT21 PLUS Prenatal Testing Service
3. SCOLR Pharma Welcomes Clem Calabrese as Director of Field Sales
4. SOCMAs Bulk Pharmaceuticals Task Force Welcomes House Passage of FDA Reform Act
5. Global BioClinical Welcomes Jennifer Maas as Senior Consultant
6. Oriel STAT A MATRIX Welcomes New Global Practice Head for Medical Devices and Life Sciences
7. Draeger Welcomes NIOSH Investigation Report
8. Thomson Reuters Welcomes Inova Software to Its Partner Ecosystem for Life Sciences
9. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
10. Nile Therapeutics Appoints Darlene Horton, M.D., as Chief Medical Officer
11. Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
(Date:12/8/2016)... Australia Glaucoma Surgery Devices Market Outlook ... "Australia Glaucoma Surgery Devices Market Outlook to 2022", ... Surgery Devices market. The report provides value, in ... average prices (USD) within market segement - Glaucoma ... shares and distribution shares data for each of ...
(Date:12/8/2016)... -- The global biosurgery market is expected to grow at ... 2016 to 2021. The market is poised to reach ... in 2016. The market is primarily driven by rising ... and spinal problems, increasing clearance of biosurgery products by ... management. In this report, the biosurgery market ...
Breaking Medicine Technology:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... Ball at The Pierre Hotel in New York, NY, on December 3rd, to ... dignitaries and physicians attended the annual event, which raised over $1 million - ...
(Date:12/8/2016)... WV (PRWEB) , ... December 08, 2016 , ... ... it will become Quality Insights beginning January 1, 2017. The name change ... its commitment to measuring and improving health care quality. , “We are very ...
(Date:12/8/2016)... ... 08, 2016 , ... ZyDoc , a New York-based ... Data Capture Methods for Input to Electronic Health Records: A Comparative Usability Study” ... comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s MediSapien™ ...
(Date:12/8/2016)... ... 2016 , ... With the increasing demand for dental implants, the National Association ... to inform dentists and patients about the safety issues related to dental restorations. According ... the U.S. is projected to reach $6.4 billion in 2018 with more than 30 ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... continuity to its innovative Unified Instance Manager architecture, meeting the needs of ... new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, provides ...
Breaking Medicine News(10 mins):